December 6, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting

TOKYO, Japan, December 6, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") announced on December 5, 2016 (EST) the presentation of Phase 2 data from the oral rigosertib and azacitidine combination trial in patients with higher-risk myelodysplastic syndromes (MDS) at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California, taking place from December 3 to 6, 2016.

The data on the efficacy and safety of oral rigosertib and azacitidine combination for 33 MDS patients (20 HMA naïve; 13 HMA resistant) was presented at the poster presentation, "Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study." The complete remission (CR) rate amongst HMA-naïve patients was higher (35%) and responses occurred more rapidly and durably with the oral rigosertib combination compared to the historic single-agent azacitidine. The median duration of CR was 8.0 months, comparing very favorably to the historic duration of CR of 3.2 months with single-agent azacitidine. For more details in this press release, please visit Onconova's homepage at http://investor.onconova.com/releases.cfm

The enrollment of patients is presently underway in a global randomized Phase 3 INSPIRE trial for IV rigosertib in second-line MDS patients in the U.S., Europe and Japan. Onconova is also now making efforts toward finalizing the design for a pivotal Phase 3 oral rigosertib/azacitidine combination trial for higher-risk MDS patients.

SymBio obtained the licensing rights for rigosertib from Onconova in July, 2011 and retains the development rights for Japan and Korea.

About Myelodysplastic Syndromes (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). The number of MDS cases are expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and higher-risk MDS.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit http://www.onconova.com.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.